Doug Marcotte
Overview
Explore the profile of Doug Marcotte including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
63
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ma B, Marcotte D, Paramasivam M, Michelsen K, Wang T, Bertolotti-Ciarlet A, et al.
PLoS One
. 2016 Nov;
11(11):e0165983.
PMID: 27832137
MLKL is a pore forming pseudokinase involved in the final stage of necroptosis, a form of programmed cell death. Its phosphorylation by RIPK3 is necessary for triggering necroptosis but not...
2.
Ishchenko A, Zhang L, Le Brazidec J, Fan J, Chong J, Hingway A, et al.
Bioorg Med Chem Lett
. 2015 Jan;
25(3):474-80.
PMID: 25575657
PIM kinases are implicated in variety of cancers by promoting cell survival and proliferation and are targets of interest for therapeutic intervention. We have identified a low-nanomolar pan-PIM inhibitor (PIM1/2/3...
3.
Argiriadi M, Goedken E, Banach D, Borhani D, Burchat A, Dixon R, et al.
BMC Struct Biol
. 2012 Sep;
12:22.
PMID: 22995073
Background: Structure-based drug design (SBDD) can accelerate inhibitor lead design and optimization, and efficient methods including protein purification, characterization, crystallization, and high-resolution diffraction are all needed for rapid, iterative structure...
4.
Zhang L, Fan J, Chong J, Cesena A, Tam B, Gilson C, et al.
Bioorg Med Chem Lett
. 2011 Jul;
21(18):5633-7.
PMID: 21798738
A novel class of pyrazolopyrimidine-sulfonamides was discovered as selective dual inhibitors of aurora kinase A (AKA) and cyclin-dependent kinase 1 (CDK1). These inhibitors were originally designed based on an early...
5.
Comess K, Sun C, Abad-Zapatero C, Goedken E, Gum R, Borhani D, et al.
ACS Chem Biol
. 2010 Nov;
6(3):234-44.
PMID: 21090814
Inhibition of protein kinases has validated therapeutic utility for cancer, with at least seven kinase inhibitor drugs on the market. Protein kinase inhibition also has significant potential for a variety...